Table 2.
Multivariable analysis by indication
| OS variable | Value or n (%) | HR (univariable, 95% CI) | HR (multivariable, 95% CI) | |
|---|---|---|---|---|
| Intrahepatic cholangiocarcinoma (ICC) | ||||
| Tumour burden (nodules) | ||||
| 1 | 35 (35.0) | - | - | |
| 2–5 | 23 (23.0) | 2.37 (1.14–4.91, p = 0.021) | 2.32 (1.04–5.19, p = 0.039) | |
| > 5 | 16 (16.0) | 3.53 (1.68–7.43, p = 0.001) | 2.49 (1.09–5.71, p = 0.031) | |
| Uncountable | 26 (26.0) | 2.54 (1.31–4.92, p = 0.006) | 3.28 (1.57–6.86, p = 0.002) | |
| Portal vein | ||||
| Patent | 83 (83.0) | – | – | |
| Segmental thrombosis | 9 (9.0) | 1.00 (0.43–2.33, p = 0.999) | 0.80 (0.32–1.98, p = 0.624) | |
| Lobar thrombosis | 4 (4.0) | 0.66 (0.16–2.70, p = 0.560) | 0.45 (0.22–0.90, p = 0.025) | |
| Main thrombosis | 4 (4.0) | 4.21 (1.44–12.29, p = 0.009) | 3.58 (1.71–7.49, p = 0.001) | |
| APRI | ||||
| ≤ 0.4 | 33 (33.0) | – | – | |
| > 0.4 | 67 (67.0) | 2.20 (1.24–3.90, p = 0.007) | 2.55 (1.25–5.23, p = 0.010) | |
| Creatinine (mg/dl) | ||||
| Mean (SD) | 1.0 (1.0) | 1.20 (1.00–1.44, p = 0.052) | 1.13 (1.00–1.27, p = 0.052) | |
| Hepatocellular carcinoma (HCC) | ||||
| Extra-hepatic disease at first treatment | ||||
| No | 339 (90.6) | - | - | |
| Yes | 35 (9.4) | 1.92 (1.27–2.89, p = 0.002) | 1.49 (0.97–2.28, p = 0.066) | |
| Liver tumour location | ||||
| Bilobar | 129 (34.5) | – | – | |
| Left | 49 (13.1) | 0.54 (0.35–0.84, p = 0.006) | 0.52 (0.27–1.02, p = 0.059) | |
| Right | 196 (52.4) | 0.49 (0.37–0.66, p < 0.001) | 0.50 (0.32–0.79, p = 0.003) | |
| Portal Vein | ||||
| Patent | 252 (67.4) | – | – | |
| Segmental thrombosis | 76 (20.3) | 1.06 (0.76–1.49, p = 0.720) | 1.36 (0.93–1.98, p = 0.113) | |
| Lobar thrombosis | 30 (8.0) | 1.41 (0.86–2.32, p = 0.169) | 1.49 (0.76–2.92, p = 0.250) | |
| Main thrombosis | 16 (4.3) | 2.46 (1.39–4.34, p = 0.002) | 2.40 (1.41–4.09, p = 0.001) | |
| Dosimetry model | ||||
| BSA/mBSA | 202 (54.3) | – | – | |
| Partition | 170 (45.7) | 0.52 (0.39–0.69, p < 0.001) | 0.70 (0.44–1.10, p = 0.125) | |
| APRI | ||||
| ≤ 0.7 | 166 (44.4) | – | – | |
| > 0.7 | 208 (55.6) | 1.44 (1.10–1.89, p = 0.008) | 1.46 (1.04–2.06, p = 0.028) | |
ICC: Samples in model = 98, Concordance = 0.703 (SE = 0.036), R2 = 0.263, Likelihood ratio test = 29.929 (df = 8, p < 0.001)
HCC: Samples in model = 368, Concordance = 0.672 (SE = 0.022), R2 = 0.167, Likelihood ratio test = 67.193 (df = 8, p < 0.001)
OS, overall survival; HR, hazard ratio; CI, confidence interval; SD, standard deviation; APRI, Aspartate Aminotransferase to Platelet Index; BSA, body surface area; SE, standard error; df, degrees of freedom